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Familial renal glucosuria (FRG) is an inherited renal tubular
disorder characterized by persistent isolated glucosuria in the
absence of hyperglycemia. Mutations in the sodium/glucose
co-transporter SGLT2 coding gene, SLC5A2, were recently
found to be responsible for the disorder. Here, we report the
molecular and phenotype study of five unrelated FRG
families. Five patients were identified and their family
members screened for glucosuria. SLC5A2 coding region of
index cases was polymerase chain reaction amplified and
sequenced. Five different mutations are reported, including
four novel alleles. The IVS12þ 1G4A and p.A102V alleles
were identified in homozygosity in index patients of two
unrelated families. A proband from another family was
compound heterozygous for the p.R132H and p.A219T
mutations, and the heterozygous p.Q167fsX186 frameshift
allele was the only mutation detected in the affected
individual from an additional pedigree. For the remaining
family no mutations were detected. The patient homozygous
for the p.A102V mutation had glucosuria of 65.6 g/1.73 m2/
24 h, evidence of renal sodium wasting, mild volume
depletion, and raised basal plasma renin and serum
aldosterone levels. Our findings confirm previous
observations that in FRG, transmitted as a codominant trait
with incomplete penetrance, most mutations are private. In
the only patient with massive glucosuria in our cohort there
was evidence evocative of renin–angiotensin aldosterone
system activation by extracellular volume depletion induced
by natriuresis. Definite proof of renin–angiotensin
aldosterone system activation in FGR should rely on
evaluation of additional patients with massive glucosuria.
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Familial renal glucosuria (FRG) (McKusick 233100) is
characterized by normal fasting serum glucose concentration
and persistent isolated glucosuria, with a normal glucose
tolerance test. It is inherited as a codominant trait with
variable penetrance.1 The SLC5A2 gene, mapping to 16p11.2,
encodes the low-affinity sodium/glucose co-transporter
SGLT2 that accounts for reabsorption of the bulk of the
filtered glucose. Selected as a major candidate gene,2,3 the
first report of an SLC5A2 mutation in FRG was presented in
2000.4 More recent studies have confirmed that mutations in
SLC5A2 are indeed responsible for the large majority of FRG
families.1,5–9 After our previous report,6 we were able to
collect five additional families. Here, we present molecular
and phenotype analysis regarding these families.
RESULTS
Phenotype evaluation
Eight affected individuals were identified among five SLC5A2
families (Figure 1). Families 2 and 5 were consanguineous.
Glucose excretion in patients with isolated renal glucosuria
and their relatives is displayed in Table 1, together with
mutation analysis. The affected individual from family 5 was
the only patient presenting with massive glucosuria of 65.6 g/
1.73 m2/24 h. The patient was 26 years old and weighed 70 kg
at the time of evaluation. On regular water and sodium
intake, arterial blood pressure was 90/60 at rest, hematocrit
and 24 h urine volume ranged from 0.49 to 0.51 and 1900 to
2250 ml, respectively, with a daily urine excretion of 70 g of
glucose and of 280 mmol of sodium. Plasma glucose
(93 mg%), sodium (139 mmol/l), chloride (101 mmol/l),
potassium (4.6 mmol/l), calcium (2.39 mmol/l), phosphate
(1.23 mmol/l), and creatinine (1.02 mg%) concentrations
were within normal range. Basal plasma renin was 7757 pg/
ml/h (reference range from 150 to 2200) and aldosterone
31.8 ng/dl (normal, 1–16).
Mutation analysis
We identified five different mutations, including four novel
alleles. In family 1 only one mutated allele was identified and
in family 4 no mutations were detected in the coding region
of SLC5A2. Patient I.2 in family 1 was heterozygous for the
c.500delA allele, the only mutation identified. In addition,
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four novel mutations are reported. These include the
IVS12þ 1G4A and c.305C4T alleles found in homozygo-
sity in index patients of consanguineous families 2 and 5,
respectively. Patient II.1 in family 3 is compound hetero-
zygous for the c.395G4A and c.655G4A mutations. The
c.305C4T and c.395G4A alleles modify the wild-type HaeII
restriction pattern of exon 4 amplicon, and therefore enabled
polymerase chain reaction-restriction-fragment length poly-
morphism testing of 100 control chromosomes. Similarly, the
IVS12þ 1G4A mutation creates an additional NlaIII
restriction site in exon 12 amplicon. As the c.655G4A allele
introduced no differences in exon 6 amplicon restriction
pattern, we sequenced 40 control chromosomes to exclude a
common polymorphism.
DISCUSSION
The SLC5 family comprises over 220 members, including 11
members of the human genome.10 Most members share a
common core of 13 transmembrane helices, although the
number of transmembrane helices may change among
homologues as in the case of human SGLT1 and SGLT2,
with 14, or in yeast DUR3, with 15.11 Additionally, there is a
functional similarity among them, despite the fact that
transported solutes range from sugars to inorganic anions. In
renal proximal tubular epithelia, two sodium/glucose
co-transporters are responsible for the reabsorption of the
filtered glucose. SGLT2, expressed almost exclusively in the
kidney,12 is a low-affinity sodium/glucose co-transporter
responsible for the bulk of glucose reabsorption. SGLT1,
which is a high affinity co-transporter strongly expressed
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Figure 1 | Pedigrees and sequences variations of the five index
cases with familial renal glucosuria. Affected individual from family
3 is compound heterozygous, whereas in consanguineous families 2
and 5, homozygous mutated alleles are displayed. Nucleotides are
numbered according to SLC5A2 cDNA sequence, except for the splice
donor mutation (wt: wild type).
Table 1 | Mutation analysis and glucose excretion in affected individuals and their relatives
Family members (agea) Country of origin Glucose excretion (g/1.73 m2/24 h) Allele 1 Allele 2
Family 1 Portugal
I.2 (50) 7.6 c.500delA; p.R167fsX186 wt
II.1 (21) 0 wt wt
II.2 (24) 0 wt wt
Family 2 Turkey
I.2 (40) 11.6 IVS12+1G4A wt
II.1 (15) 0 wt wt
II.2 (08) 6.4 IVS12+1G4A IVS12+1G4A
II.3 (03) 12.2 IVS12+1G4A IVS12+1G4A
Family 3 Turkey
I.1 (23) 0 c.395G4A; p.R132H wt
I.2 (28) 0 wt c.655G4A; p.A219T
II.1 (01) 6.2 c.395G4A; p.R132H c.655G4A; p.A219T
Family 4 Turkey
I.1 (30) 2.2 nd nd
I.2 (32) 0 nd nd
II.1 (12) 0 nd nd
II.2 (06) 12.1 wt wt
Family 5 Turkey
II.1 (26) 65.6 c.305C4T; p.A102V c.305C4T; p.A102V
an years, at time of evaluation.
nd, not determined; wt, wild type; 0, no glucosuria by dipstick method.
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in the small intestine and kidney,3,13 accounts for the
reabsorption of the remaining glucose. SGLT1 defects
are known to be associated with familial intestinal
glucose-galactose malabsorption (McKusick 606824)14,15
and patients with this condition have only mild glucosuria.
The first report of an SLC5A2 mutation in FRG was presented
in 2000,4 followed by a case report of an affected individual
homozygous for a nonsense mutation.5 Later, an extended
study of 23 affected families reported 21 different SLC5A2
mutations, most of them private.1 We then reported
a compound heterozygote son of non-consanguineous
marriage,6 and since then only three other reports have
been published to our knowledge,7–9 We now present
molecular and phenotype findings in five additional
unrelated families.
Patient I.2 from family 1 displays a heterozygous
c.500delA frameshift mutation in SLC5A2 exon 5, leading
to a premature stop at position 186 (p.Q167fsX186). This
allele has been previously reported.1,6 The c.500delA frame-
shift truncating mutation occurs at the beginning of 12th
transmembrane helix, one of the crucial transmembrane helix
for the sugar translocation pathway.3
The IVS12þ 1G4A mutation in affected members of
family 2 is a novel mutation in the consensus donor splice
sequence of intron 12. This can lead to intron retention, exon
skipping, or indirect activation of a cryptic splice site. In
glucose-galactose malabsorption, SGLT1 splice site mutations
were shown to produce nonfunctional truncated proteins.16
In this family, the heterozygous father and the homozygous
infantile sons excreted similar amounts of glucose. We can
only speculate about the possibility that as these homozygous
affected children grow older, the amount of excreted glucose
will increase, reaching a massive range at adult age that will
be significantly greater than their heterozygous father. In
addition, it is possible that other glucose transporters may
interfere with the overall net renal glucose excretion.
Patient II.1 from family 3 excretes 6.2 g/1.73 m2/24 h of
glucose and is compound heterozygous for the c.395G4A
and c.655G4A alleles, both being novel missense mutations.
The c.395G4A allele, inherited from the mother, lies in exon
4 and results in His for Arg at position 132 (p.R132H) within
the second internal domain of SGLT2. Arg 132 seems to play
an essential structural role, given that it is one of the four
residues that are perfectly conserved among all SGLT family
members, the other three being Gly92, Gly192, and Gly193.11
Mutations involving this residue in SGLT1 were found to
completely inactivate sugar transport.15 On the other hand,
the c.655G4A allele in exon 6, results in a nonconservative
Thr for Ala replacement at position 219 (p.A219T). There-
fore, both these alleles, one affecting a conserved residue, the
other being a nonconservative substitution, may have an
impact on SGLT2 glucose transport activity.
After sequencing the entire coding region of the SLC5A2
gene, no mutations were found in family 4. It is possible that
a mutation residing in the promoter or a heterozygous large
deletion not detectable by polymerase chain reaction might
have occurred, or that another gene may be responsible for
FRG in this particular family.
Patient II.1 in family 5 is a son of a consanguineous
marriage and was 26 years old at the time of evaluation. He is
homozygous for the novel c.305C4T allele in exon 4, leading
to the conservative Val for Ala substitution in residue 102, at
the beginning of the third transmembrane helices. Contrast-
ing to Arg 132, Ala 102 is not highly conserved among all
members of the SLC5 family. Remarkably, however, it is a
conserved residue in those members known to co-transport
glucose across plasma membranes like SGLT1, SGLT2, and
SMIT. In human SGLT3, encoded by the SLC5A4 gene, the
Ala residue is replaced by Ser. However, SGLT3 is not a
cotransporter, but rather a glucose-gated ion channel
expressed in cholinergic neurons and at the neuromuscular
junction.10 For the least divergent hSGLT3 homolog, which is
pigSAAT1,10 the equivalent residue is again an Ala. Interest-
ingly, SAAT1 was initially reported as a sodium-dependent
neutral amino-acid transporter, but as now been renamed
pigSGLT3 because it was later found that it encodes a low-
affinity sodium/glucose cotransporter.17 We can therefore
suppose that the Ala 102 residue in those SLC5 members that
co-transport glucose may play a critical role in the symporter
function. Patient II.1 from family 5 is the only one in our
cohort presenting massive glucosuria, with 65.6 g/1.73 m2/
24 h. FRG is considered to be a benign condition, more of a
phenotype than a disease. There have been occasional reports
of polyuria in FRG, mainly in patients with massive
glucosuria, who are distinctly rare. Although most of the
sodium loss from the proximal nephron is reabsorbed in the
more distal nephron, we hypothesized that some could
escape this compensatory mechanism and that FRG could be
similar to other salt-wasting nephropathies, particularly in
the case of severe glucosuria. Our findings are in line with
previous observations as of polyuria being the major
functional change in FRG.18 At the time of evaluation,
patient II.1 from family 5 had evidence of moderate
extracellular volume depletion, in the absence of other
known causes. Basal plasma renin activity and serum
aldosterone were significantly raised. Although based on a
single determination, these findings possibly reflect second-
ary renin–angiotensin aldosterone system activation by
volume contraction.
In conclusion, we have screened five additional FRG
pedigrees for mutations in the coding region of the SLC5A2
gene and found five mutations in four unrelated families,
including three missense and one donor splice novel
mutations. We consider our findings of relevance, because
in the absence of a functional expression assay for SGLT2,
mutation reporting is crucial for unraveling critical residues
in the protein and their impact in the symporter activity. Our
small cohort of families seems to confirm that the pattern of
inheritance that best applies in FRG is one of codominant
trait with incomplete penetrance. However, this paper also
illustrates that establishing definite genotype/phenotype
correlations is probably an impossible task, as other genes
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involved in renal glucose transport may amplify or
compensate for SLC5A2 mutants. Also, in the only patient
with massive glucosuria, we have documented natriuresis and
polyuria that could lead to extracellular volume depletion
and possible renin–angiotensin aldosterone system activation.
This latter finding needs confirmation in additional patients
with massive glucosuria.
MATERIALS AND METHODS
Patients and phenotype evaluation
Five unrelated families were studied. One was of Portuguese origin
and four originated from Turkey, although one affected descendent
was living in Austria at the time of diagnosis. The pedigrees are
shown in Figure 1. After obtaining written consent from participat-
ing individuals or their legal guardians, 15 individuals were
evaluated. Generalized tubular proximal dysfunction had been
excluded in our FRG families before referral. Relatives were screened
for the presence of glucosuria by dipstick urinalysis. Glucosuria was
quantified in a 24-h urine collection in those found to be positive by
dipstick determination. Only one patient presented with massive
glucosuria (450 g/1.73 m2/24 h). This individual had basal plasma
renin and aldosterone assessed, in order to evaluate renin–angio-
tensin aldosterone system stimulation by extracellular volume
depletion.
Mutation analysis
Genomic DNA was isolated from peripheral blood leucocytes. The
coding region of the SLC5A2 gene was screened for mutations by
direct sequencing of polymerase chain reaction products as
previously reported.6 Mutations were confirmed by bidirectional
sequencing and we tested control chromosomes by polymerase
chain reaction-restriction-fragment length polymorphism or direct
sequencing, to ensure that they do not represent common
polymorphisms.
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